传奇生物 LEGN 深 沪
已收盘 10-02 16:00:00 美东时间
18.57
-0.750
-3.88%
华盛通- 最 高19.64
- 今 开19.35
- 成交量 252.96万股
- 最 低 18.52
- 昨 收 19.32
- 总市值 36.12亿
- 52周最高 37.50
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 16.24
- 委 比 25.93%
- 总股本 1.94亿
- 历史最高 77.32
- 量 比 1.23
- 振 幅 5.80%
- 历史最低 16.24
- 每 手 1
- 风险率 5.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多传奇生物新任高级副总裁，来自百济神州
9月29日，Josh Schwartz 在LinkedIn上发布动态，宣布告别百济神州，出任传奇生物高级副总裁（SVP）一职。 Josh ...
09-29 18:01
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today a...
09-25 19:03
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech announced five-year follow-up data from the CARTITUDE-2 Cohort A study, showing that 50% of patients with relapsed/refractory multiple myeloma (RRMM) remained alive and progression-free after a single infusion of CARVYKTI (ciltacabtagene autoleucel). The five-year overall survival rate was 69.2%, highlighting the potential of CARVYKTI to achieve durable, treatment-free remission when used earlier in the treatment journey. These fin...
09-25 11:00
围观！诺华前中国区总裁张颖新东家敲定！
2026年9月15日，美国纳斯达克上市传奇生物（LEGN.US）宣布，董事会已任命张颖（Ingrid Zhang）为首席执行官，自2026年9月15日起生效。...
09-16 11:15
诺华前中国区总裁张颖，出任传奇生物CEO！
（来源：药研网） 9月15日，传奇生物宣布，董事会已任命张颖为首席执行官，自2026年9月15日起生效。张颖将接替自2026年7月起出任临时首席执行官的Ala...
09-16 09:22
Legend Biotech appoints Ingrid Zhang as CEO
Legend Biotech (LEGN) on Tuesday appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Zhang succeeds Alan Bash, who has served as interim CEO since July 2026. Most recently...
09-15 20:18
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech appoints Ingrid Zhang as CEO, effective September 15, 2026, following a comprehensive search. Zhang, a seasoned global biopharmaceutical leader with extensive experience at Novartis, AstraZeneca, and Pfizer, succeeds Alan Bash, who will resume his role as President of CARVYKTI. The Board believes Zhang’s strategic vision and operational expertise will drive the company’s growth and innovation in cell therapy.
09-15 12:00
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
华盛早报 | AI利空突袭？科技三巨头支持放缓AI研究；机构称美联储年内或连续加息三次；智谱融资50亿美元全力押注RSI领域
AI利空突袭？科技三巨头支持放缓AI研究；沙特能源动脉中断！油价拉升2%，纳指期货跌逾1%；智谱50亿美元新融资落地！拟全力押注RSI领域>>
09-14 08:35
美股三大指数止跌反弹 芯片股走强费城指数涨近2%
9月11日，受国际油价回落影响，美股三大指数集体收涨，道指涨0.98%，本周累跌1.57%；纳指涨0.96%，本周累跌0.66%；标普500指数涨0.86%，本...
09-12 09:46
